{"brief_title": "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma", "brief_summary": "The objectives of this study are to determine the safety and activity profile of multiple doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy (decarbazine [DTIC]) can augment the effects of MDX-010 in patients with chemotherapy na\u00efve metastatic melanoma with a tolerable toxicity profile.", "condition": "Melanoma", "intervention_type": "Drug", "intervention_name": "MDX-010 (CTLA-4)", "criteria": "Inclusion Criteria - Clinical diagnosis of unresectable metastatic melanoma. - No prior chemotherapy for melanoma, and no chemotherapy for other malignancies within 5 years and at least 4 weeks since treatment (surgery, radiation, or immunotherapy) for melanoma. Exclusion Criteria Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study: - Any other prior malignancy, except for the following: adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for >=5 years. - Active autoimmune disease. - Active infection requiring therapy, or chronic active HBV or HCV, or confirmed reactivity with HIV tests.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00050102.xml"}